[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100630695":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":11,"locations":17,"responsibleParty":32,"collaborators":10,"id":35,"slug":10,"hasResults":36,"nctId":37,"briefTitle":38,"officialTitle":39,"acronym":10,"eligibilityCriteria":40,"healthyVolunteers":36,"sex":41,"minAge":42,"maxAge":43,"enrollmentInfo":44,"targetDuration":10,"studyType":47,"phases":10,"briefSummary":48,"conditions":49,"keywords":10,"overallStatus":19,"whyStopped":10,"lastUpdateSubmitDate":53,"lastUpdatePostDateStruct":54,"startDateStruct":57,"completionDateStruct":59,"leadSponsor":61,"locationsCount":62},{"fullName":5,"class":6},"Zhejiang Provincial People's Hospital","OTHER",[8],{"label":9,"type":10,"description":10,"interventionNames":10},"Telitacicept; Baricitinib. One group of D2TRA subjects receive Telitacicept combine Baricitinib",null,[12],{"name":13,"role":14,"phone":15,"phoneExt":10,"email":16},"Zhenhua Ying","CONTACT","+86-571-3989897128","yingzh2021@163.com",[18],{"facility":5,"status":19,"city":20,"state":21,"zip":22,"country":23,"cosmosGeoPoint":24,"geoPoint":29,"contacts":30},"RECRUITING","Hangzhou","Zhejiang","310000","China",{"type":25,"coordinates":26},"Point",[27,28],120.16142,30.29365,{"lat":28,"lon":27},[31],{"name":13,"role":14,"phone":15,"phoneExt":10,"email":16},{"type":33,"investigatorFullName":13,"investigatorTitle":34,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Chief Physician","100630695",false,"NCT07491016","Efficacy and Safety of Telitacicept Combined With Baricitinib for Refractory Rheumatoid Arthritis","A Study on the Clinical Efficacy and Safety of Telitacicept Combined With Baricitinib in the Treatment of Difficult-to-Treat Rheumatoid Arthritis (D2T RA)","Inclusion Criteria:\n\n* 1\\. Age 18-85 years\n* 2\\. Diagnosed with refractory rheumatoid arthritis according to the 2021 EULAR (European Alliance of Associations for Rheumatology) diagnostic criteria\n* 3\\. The traditional disease-improving rheumatic drug treatment is ineffective, and the use of two or more biological\u002Ftargeted disease improving anti-rheumatic drugs is ineffective, and telitacicept combined with tofacitinib is required treated patients\n* 4\\. Voluntarily provided written informed consent\n\nExclusion Criteria:\n\n* 1\\. Exclusion of patients with severe diseases of major organs (e.g., heart, liver, or lungs)\n* 2\\. Patients with malignancies, hematological disorders, or other autoimmune diseases (excluding rheumatoid arthritis)\n* 3\\. History of allergy\u002Fhypersensitivity to the study medications (Telitacicept or Tofacitinib)\n* 4\\. Active tuberculosis or active infectious diseases requiring systemic treatment\n* 5\\. Pregnancy, lactation, or refusal to use contraception during the study\n* 6\\. Failure to complete the prescribed Telitacicept + Tofacitinib regimen due\n* to:Non-adherence or Severe adverse reactions\n* 7\\. Other conditions contraindicating participation per investigator judgment","ALL","18 Years","85 Years",{"count":45,"type":46},30,"ESTIMATED","OBSERVATIONAL","The aim of this study is to observe the clinical efficacy and safety of telitacicept combined with baricitinib in the treatment of D2TRA patients",[50,51,52],"Telitacicept","Treatment Compliance","Rheumatoid Arthritis","2026-03-24",{"date":55,"type":56},"2026-03-30","ACTUAL",{"date":58,"type":46},"2026-03-01",{"date":60,"type":46},"2028-03-30",{"name":5,"class":6},1]